Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma

November 22nd 2025

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma

November 12th 2025

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma

November 3rd 2025

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

FDA Grants Orphan Drug Designation to Exosome-Based Therapy for Glioblastoma Multiforme

October 30th 2025

The FDA granted orphan drug designation to an exosome-based therapy for glioblastoma multiforme.

Selumetinib Nets EU Approval for Adult NF1-Associated Plexiform Neurofibromas

October 28th 2025

Selumetinib has received approval in the EU for the management of plexiform neurofibromas in adult patients with neurofibromatosis type 1.

FDA Awards Fast Track Designation to MT-125 for Glioblastoma

October 28th 2025

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

FDA Grants Orphan Drug Designation to Cintredekin Besudotox in Glioblastoma

October 10th 2025

The regulatory agency has granted orphan drug designation to cintredekin besudotox for the treatment of patients with glioblastoma.

OncLive’s September EMA Regulatory Recap: Key EU Approvals in Oncology

October 2nd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma

October 2nd 2025

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Dr Vojnic on Vorasidenib in Grade 2 IDH1/2-Mutated Glioma

September 26th 2025

Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.

Dr Sherman on Advances in Surgical Brain Tumor Management

September 26th 2025

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.

Selumetinib Earns Positive CHMP Opinion for Adult NF1-Associated PNs

September 23rd 2025

CHMP has recommended the approval of selumetinib for symptomatic, inoperable plexiform neurofibromas (PNs) in adult neurofibromatosis type 1.

Vorasidenib Nets European Approval in IDH1/2-Mutated Grade 2 Glioma

September 22nd 2025

Vorasidenib has been approved by the European Commission for IDH1/2-mutated grade 2 glioma.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas

September 10th 2025

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

Dr Monje on the Role of a Novel GD2-Directed CAR T-Cell Therapy in Diffuse Midline Glioma

September 9th 2025

Michelle Monje, MD, PhD, discusses the early efficacy of a novel GD2-directed CAR T-cell therapy for the treatment of children with diffuse midline glioma.

NCCN Adds Dordaviprone to Clinical Practice Guidelines in H3K27M-Mutant Diffuse High-Grade Glioma

September 9th 2025

Dordaviprone was included as a category 2A single agent in the NCCN guidelines for recurrent or progressive H3K27M-mutant diffuse high-grade glioma.

New Genetic Biomarker Flags Aggressive Brain Tumors

September 8th 2025

A new study suggests that if a tumor shows activity in the TERT gene, it tends to recur more quickly, even if it looks low-grade under the microscope.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

GD2-Directed CAR T-Cell Therapy Generates Early Antitumor Activity in H3K27M-Mutant Diffuse Midline Glioma

September 3rd 2025

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.